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Renin inhibition has been evaluated for a new class of fluorinated ketones, true analogues of peptides that have been 
retroinverted at the C-terminal position. The readily formed hydrate of the ketone is proposed to mimic the tetrahedral 
intermediate that occurs during the enzyme-catalyzed hydrolysis of amide linkage. From this series of compounds it ap- 
pears that the number of reverted amide bonds is crucial in terms of activity. Furthermore, a shortening of the C-terminal 
part of our peptide analogues and the replacement of the leucine residue in P, by a cyclohexylalanine l ads to the tripep- 
tide analogue 12 a potent renin inhibitor (IC,, = 3.5 ~10-~ M). 
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1. INTRODUCTION 
The renin-angiotensin system (RAS) plays a cen- 
tral role in the regulation of blood pressure and 
electrolyte homeostasis [ 1,2]. Renin (EC 
3.4.99.19), an aspartyl protease, is the enzyme 
responsible for cleaving a decapeptide fragment 
from the N-terminal portion of angiotensinogen. 
This highly specific and rate limiting step initiates 
the renin-angiotensin converting enzyme cascade. 
The search for an orally active inhibitor of 
human renin for the treatment of hypertension has 
intensified greatly over the past few years [3]. 
It has been known for some time that much of 
the catalytic specificity and efficiency of aspartate 
proteases derives from binding interactions that oc- 
cur throughout the extended active site [4]. As a 
consequence, the minimum synthetic substrate 
known for renin is an octapeptide [5], and renin in- 
hibitors have tended to be rather large. This seem- 
ingly necessary size and the peptide character of 
renin inhibitors, led to compounds that had serious 
problems of metabolism, oral bioavailability and 
duration of action [5]. Thus, the challenge in this 
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field is to minimize those features. Steady progress 
toward this goal has been made over the past three 
years. 
In the present work we wish to report a new 
series of small peptide analogues, whose original 
structure is the result of the combination of fluo- 
roketone and retroamide type bonds [6]. The 
potency of fluoroketone derivatives as inhibitors of 
hydrolytic enzymes has been well documented and 
illustrated [7]. In the case of zinc metallo- and 
aspartyl proteases, they are assumed to be transi- 
tion state analogues due to their high propensity to 
act in their carbonyl hydrated form. As a result, 
several renin inhibitors bearing difluorostatone or 
perfluoroketone have been reported recently [8,9]. 
The potent inhibitory action of the latter peptides 
prompted us to synthesize new extended binding 
type fluoroketones [ 10,111. These inhibitors incor- 
porate a dipeptide surrogate of leucine-glycine or 
cyclohexylalanine-glycine. 
Our approach lies in the design of fluorinated 
peptide analogues that have been retroinverted at 
the C-terminus. These compounds are chemically 
stable [12]. Moreover, enhanced resistance to 
biodegradation processes might be an additional 
benefit of this type of structural modification. The 
inhibitory potency of these compounds against 
human plasma renin is presented here. 
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2. MATERIALS AND METHODS 
2.1. Renin assay 
A human plasma pool containing 10 mM EDTA stored at 
0°C and rich in renin, was incubated for 90 min at 37”C, pH 
6.0, in the presence of 1.5 mM PMSF (phenyl methyl sulfonyl 
fluoride) and increasing concentrations of inhibitors. The in- 
hibitors were added to the assay medium from a stock solution 
in MezSO. The presence of 1% MezSO in the final incubation 
mixture had no significant effect on the renin activity. 
The radioimmunoassay for angiotensin I was carried out with 
a commercially available kit (clinical assays: SB RENZ, 
available from CEA). 
Plasma renin activity values for assays containing inhibitor 
were compared to control assays to estimate the percent of in- 
hibition. The inhibition results were expressed as I&, values 
(concentration of test product causing 50% inhibition of plasma 
renin activity). 
2.2. Chemical synthesis 
The compounds described in this study were synthesized by 
the following methods: Cbz-L-cY-aminoaldehyde was condensed 
with ethyl bromodifluoroacetate in the presence of activated 
zinc. The resulting cu,cu-difluoro-&hydroxyester was converted 
in two steps to the corresponding B,,&difluoro-y-hydroxyamine 
by the procedure in [12]. The 1,Cdiamine was isolated in its 
diprotected form. The N-Cbz-N’-Boc-1,Cdiamine was depro- 
tected sequentially and coupled to carboxylic acids (on the car- 
boxy1 terminus) and N-protected dipeptides (on the amino ter- 
minus) [12] to yield the precursor difluoroalcohol. Oxidation of 
the difluoroalcohols to the final difluoroketones was performed 
using pyridinium dichromate 112). 
Complete details of the chemical synthesis will be reported 
elsewhere. 
3. RESULTS AND DISCUSSION 
The peptides analogues that were prepared in 
this study along with the corresponding 1C50 values 
against human plasma renin are shown in tables 1 
and 2. The choice of the general amino acid se- 
quence of the reported peptide analogues was dic- 
tated by both the enzyme specificity and inhibitor 
synthesis requirements. Regarding the latter con- 
sideration, a norvaline residue was incorporated in 
place of the normally occurring PZ histidine, since 
it is known that this rtiplacement should not affect 
the binding [ 131. 
General comments on this type of peptide are 
2-fold. First, as observed previously [7-111 for 
other types of fluorinated renin inhibitors, ketones 
3 and 4 are more potent than their corresponding 
alcohols (1 and 2, respectively). Secondly, as an- 
ticipated [ 13,141, the nature of the amino terminal 
substituent plays a role in the affinity, the Boc 
derivative 4 being 6 times more potent than the Cbz 
48 
Table 1 
Inhibition of human plasma renin 
Human Phe His Leu Val Ile His I&O (nh 
angiotensinogen Pj P2 PI P’, P’z P’1 
2 
7 BocPhenVal WI J3- 
8 BocPhenVal ?w~2~m~ ‘45o 
0 0 
3. Inhibitor 4 was our lead compound for the struc- 
tural modifications which follow. 
Introducing additional retroamide bonds [ 151 
between the P’ residues of the peptides led to the 
important observation that the total number of 
such modifications seems to be important in terms 
of activity. In this respect, fluoroketone 5, which 
bears two retroamide peptide bonds, is much less 
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Table 2 
Inhibition of human ulasma renin 
Pa Pz Pl P’l p’z P ‘3 Go (nM) 
15 
BocPhenVal NH 
dbf 
cF2_M 
0 0 0 
BocPhenVal Ni 
BocPhenVal NM 
0 0 
BocPhenVai WI 
BocPhenVal NH 
BocPhenVal NH 
BocPheLeu NH 
/e 
-3 
0 
1500 
25 
250 
40 
3.5 
30 
30 
2509 
* See [17] 
active than fluoroketone 4 bearing only one 
retroamide linkage. 
Interestingly, compound 8 which is lacking one 
peptide bond at the carboxy terminus, is equipo- 
tent to 4 suggesting that this particular amide is not 
implicated in any hydrogen bonding. 
Changes in the size of the side chain of the P’2 
residue induces less dramatic changes in the affini- 
ty. The replacement of the isopropyl side chain of 
P’2 in inhibitor 4 by a methyl (6) or a hydrogen (7) 
had a very small effect on ICSO values with com- 
pound 7 being only three times more potent than 6 
or 4. This might suggest a very slight steric effect of 
P’2 in 4 or 6. 
The structure activity relationship at the Pl site 
was also investigated. In agreement with a 
previously reported result [la], an enormous im- 
provement in affinity was observed by substituting 
the isobutyl side chain in Pl of 4 by a cyclohexyl 
methylene moiety. Compound 9 is 60 times more 
effective than 4. We can assume that this particular 
side chain fits the Sl subsite of the active site in an 
optimal fashion. This result is impressive when 
compared to the disappointing observation of 
Thaisrivong et al. [8] for difluorostatone contain- 
ing inhibitors, in which such a modification had no 
effect. Based on these two contradictory results, we 
can anticipate that the two families of fluorinated 
ketones bind differently to renin. Although the 
concept of difluorostatone has generated some of 
the most potent inhibitors of human renin (com- 
pare 4 to 14), the interesting effect of the incor- 
poration of the cyclohexyl methyl side chain in the 
P 1 position of our retroinverted fluoroketone leads 
to an inhibitor equipotent to the difluorostatone 
containing peptide (compare 9 to 14). 
An additional aim of our work was to further 
define the importance of the carboxy terminal part 
of this type of molecule in terms of activity. The 
most interesting feature in this series of peptide 
analogues was that a shortening of the carboxy ter- 
minus as in ketone 10 or 11 yielded inhibitors 6 and 
40 times more active than 4, respectively. There- 
fore, we investigated some further modifications 
on this part of our inhibitors. It is clear that the 
isovaleryl substituent at the carboxy terminus of 11 
and 12, when compared to an isobutyloxycarbonyl 
moiety in 10 or an acetyl group in 13, provides the 
best fit with the enzyme. This is logical if we con- 
sider the isovaleryl side chain as a good mimic of 
the P’2 isoleucine residue of human angiotensi- 
nogen. Moreover this would suggest hat this side 
chain binds tightly to the S’2 subsite of human 
renin. 
Finally, the combination of the shortening of the 
carboxy terminus and the replacement of the P1 
49 
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leucine of 4 by a cyclohexylalanine residue produc- 
ed the tripeptide analogue 12, which inhibits renin 
at nanomolar concentrations. 
At this stage of our study it is of interest o com- 
pare the difluoroketone containing peptide 12 with 
the recently published tripeptide trifluoromethyl 
ketone 15 [17]. These two derivatives are based on 
a quite similar peptide sequence, allowing a direct 
comparison. The additional interactions provided 
by the retroamide and the isovaleryl side chain 
make 12 about 70 times more active than 15. This 
result reinforces the concept of extended-binding 
type inhibitors for renin inhibition. 
In conclusion, the small size of our peptide 
analogues and the presence of a retroamide bond 
that should enhance both the chemical and the pro- 
teolytic stabilities provide a new possibility for the 
development of orally active renin inhibitors. Our 
progress in this respect, as well as in vivo studies, 
will be the subject of future reports. 
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